A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...